Why Ligand Pharmaceuticals Incorporated’s (LGND) Stock Is Down 9.16%
As of Monday, June 22, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 9.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated LGND
$287.54
-8.75
-2.95%
July 31, 2026 4:00:00 PM
EST
Volume: 259,861
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Commentary & Analysis
Which Is a Better Investment, Ligand Pharmaceuticals Incorporated or Trulieve Cannabis Corp. Stock?
Learn more about whether Ligand Pharmaceuticals Incorporated or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Ligand Pharmaceuticals Incorporated’s (LGND) Stock Is Up 5.12%
As of Wednesday, June 10, Ligand Pharmaceuticals Incorporated’s LGND share price has surged by 5.12%, which has investors questioning if this is right time to sell.Michael Rose
Why Ligand Pharmaceuticals Incorporated’s (LGND) Stock Is Down 9.54%
As of Thursday, May 07, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 9.54%, which has investors questioning if this is right time to buy.Michael Rose
Why Ligand Pharmaceuticals Incorporated’s (LGND) Stock Is Up 6.10%
As of Tuesday, April 14, Ligand Pharmaceuticals Incorporated’s LGND share price has surged by 6.10%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | LGND | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,870.2 | $569.9 | 70% |
|
| Shares Out (Mil) | 19.9 | 44.8 | 30% |
|
| Institutional Ownership | 97.7% | 84.6% | 75% |
|
| Float (Mil) | 19.3 | 45.1 | 28% |
|
| Beta | 1.04 | 0.67 | 62% |
|
| Avg Daily Volume (000s) | 303 | 294 | 51% |
|
| Price Change (52-week) |
125.2% | 65.2% | 94% |
|
| Growth | LGND | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.4% | 6.7% | 60% |
|
| Net Income (5yr) | 112.7% | (2.0%) | 99% |
|
| EPS (5yr) | 104.8% | 14.9% | 99 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 40.8% | (14.9%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 8 | 7 | |
| Current EPS | $1.840 | $9.184 | $11.829 | |
| Month Ago EPS | $1.990 | $9.101 | $11.317 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $2.048 | $9.248 | $11.810 | |
| Year/Year Chg | (374.2%) | 49.8% | 125.5% | |
| Financials | LGND | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $275 | $230 | 35% |
|
| Net Income (TTM) (Mil) | $154 | ($11) | 65% |
|
| EPS (TTM) | $7.870 | ($0.600) | 92% |
|
| Operating Cash Flow (TTM) (Mil) | $124 | ($6) | 54% |
|
| Net Cash Flow (TTM) (Mil) | $67 | $4 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $451 | $7 | 58% |
|
| Enterprise Value (Q1) (Mil) | $4,648 | $493 | 62% |
|
| Valuation | LGND | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.95 | 2.89 | 82% |
|
| P/E | 39.5 | 20.6 | 78% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.5 | 1.1 | 25% |
|
| Ratios | LGND | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.2% | 65.9% | 91% |
|
| Net Margin | 55.9% | (0.2%) | 97% |
|
| ROA | 12.6% | (25.5%) | 91% |
|
| ROE | 17.1% | (21.4%) | 75% |
|
| Liabilities to Assets | 34.9% | 35.5% | 26% |
|
| F-Score | 6 | 3 | 69% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 15.1% |
| +/- S&P 500: | +7.6 |
